Milestone Scientific, Inc.
Under the Symbol:
Milestone Scientific Announces Five Year Follow-Up Report by Expert and Consultant in Peripheral Nerve Block (PNB) Regional Anesthesia; Provides Validation and Confidence to Advance CompuFlo(R) in PNB Market
Tuesday, January 28, 2020 8:30 AM
PNBs represent attractive and untapped growth market for the CompuFlo technology
Key studies being submitted and under review for publication in leading industry journals
LIVINGSTON, NJ / ACCESSWIRE / January 28, 2020 / Milestone Scientific Inc. (NYSE American:MLSS) today announced a report by Dr. Olivier Choquet, a recognized international expert on peripheral nerve blocks (PNB) and a consultant to Milestone Scientific, Inc., which concludes that the CompuFlo® with Dynamic Pressure Sensing technology® is the only available device capable of precisely measuring, displaying, warning, controlling and recording needle tip pressure in real time to help reduce the risk of needle injury during PNB procedures.
Continuous peripheral nerve block procedures are becoming more prevalent, including pain management for patients undergoing upper/lower extremity surgeries and patients suffering from trauma. Additionally, peripheral nerve blocks are increasingly utilized as an attractive alternative to opioids for pain management, including orthopedic surgeries, which are considered one of the most painful surgeries.
Dr. Olivier Choquet is the Medical Director of the Emergency Surgery operating theater and a Medical Doctor in the Department of Anesthesiology in Traumatology and Orthopedics, Lapeyronie University hospital, Montpellier, France. He has more than 50 publications to his name and is a sought after expert in the area of regional anesthesia. He lectures internationally and conducts workshops at major Congresses on a regular basis. He also serves as a clinical consultant to Milestone Scientific, Inc. and has been instrumental identifying how CompuFlo's Dynamic Pressure Sensing Technology can change how PNB procedures are performed.
In 2015, Dr Choquet and his colleagues at Lapeyronie University hospital started exploring the use of the CompuFlo technology for PNB procedures to assess the optimal flow rate during PNB procedures. He went on to investigate using Dynamic Pressure Sensing technology as a means of detecting direct needle-to-nerve contact using CompuFlo, which he demonstrated. This initial research gave rise to the pursuit of developing a true multimodal monitoring concept of combining ultrasound guidance, nerve stimulation and CompuFlo Dynamic Pressure Sensing technology. A formal comparative clinical study has been conducted and is currently in review for publication in a well-respected, peer-reviewed medical journal.
Between 2016 thru 2019, Dr. Choquet and his colleagues conducted five additional research projects, in which Milestone Scientific's Dynamic Pressure Sensing technology has been studied. The preliminary results of his research have been presented at national meetings and, in 2016, he was awarded the Best Regional Anesthesia Abstract at the French Anesthesia Society Annual Meeting. Since 2019, Dr. Choquet and colleagues from the Lapeyronie University hospital Department of Paediatric and Gynecologic Anaesthesia conducted an Observational Study using the CompuFlo technology in PNB and epidural procedures in pediatric patients. Data collection is nearly complete and statistical analysis is underway. This study will be submitted for publication in 2020.
Dr. Choquet stated, "Although quite new, the concept of injection pressure monitoring has seen rapid growth and will grow even further, as evidenced by the introduction of several devices designed specifically for use during regional anesthesia and our demonstration that CompuFlo with Dynamic Pressure Sensing technology may prevent intraneural injection."
Leonard Osser, Interim CEO of Milestone Scientific, Inc. stated, "We are very excited about the research that Dr. Choquet continues to conduct, as he is on the cutting edge of regional anesthesia and his team is making important contributions to the field. I am grateful that he recognizes the value in our technology and has agreed to be part of our team. Overall, the PNB is a large, growing and untapped market for our CompuFlo technology. Although we remain laser focused on accelerating the commercialization of the epidural instrument, we are now sufficiently advanced that we are preparing our commercial pipeline in other indications."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
SOURCE: Milestone Scientific Inc.